Description

Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with 68Gallium (68Ga) for positron emission tomography (PET) imaging[1].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)–COVID-19-immunoregulation–C60H80N14O14—-[1]Buck AK, et al. CXCR4-targeted theranostics in oncology. Eur J Nucl Med Mol Imaging. 2022 Oct;49(12):4133-4144. –1341207-62-2–1221.36–99.20–O=C(NCC(N[C@@H](C1=O)CC(C=C2)=CC=C2O)=O)[C@@H](NC([C@@H](NC([C@H](N1C)CCCNC(C(C=C3)=CC=C3CNC(CN(CCN(CC4)CC(O)=O)CCN(CCN4CC(O)=O)CC(O)=O)=O)=O)=O)CCCNC(N)=N)=O)CC5=CC(C=CC=C6)=C6C=C5–Others–DMSO : 100 mg/mL (ultrasonic)|Methanol : ≥ 125 mg/mL–CXCR—-GPCR/G Protein;Immunology/Inflammation–Peptides